Rani Therapeutics (RANI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting called to order with board members and management present, including CEO and CFO.
Inspector of Election appointed and rules of conduct outlined for an orderly virtual meeting.
Notice of meeting and quorum confirmed, with 123,872,874 shares eligible to vote.
Overview of voting outcomes
Election of seven directors approved to serve until the 2027 annual meeting.
Ratification of CBIZ CPAs, P.C. as independent auditor for fiscal year 2026 confirmed.
Voting results to be reported on Form 8-K within four business days.
Board and executive committee updates
Abraham Basan and Vasudev Bailey, PhD, appointed to the Board of Directors.
Alireza Javadi, PhD, promoted to Chief Technical Officer.
Advisory appointments of Dr. Sara Kenkare-Mitra and Jesper Høiland to strengthen leadership.
Latest events from Rani Therapeutics
- Net loss narrowed to $8.0M on $1.7M revenue, with cash runway into Q4 2027 and Nasdaq delisting risk.RANI
Q1 202615 May 2026 - Shareholders will vote on director elections and auditor ratification, with strong governance in place.RANI
Proxy filing16 Apr 2026 - Vote on board elections and auditor ratification at the May 28, 2026 annual meeting.RANI
Proxy filing16 Apr 2026 - Chugai deal, debt repayment, and clinical progress drive strong financial and pipeline momentum.RANI
Q4 202526 Mar 2026 - RT-114, an oral GLP-1/GLP-2 dual agonist, targets weekly dosing and global obesity market impact.RANI
Investor Update3 Feb 2026 - Oral dual GLP-1/GLP-2 program targets obesity with weekly dosing, Phase 1 starts in 2025.RANI
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Oral biologics platform advances in obesity with strong early data and flexible dosing.RANI
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Oral biologics platform advances with differentiated obesity and immunology programs, strong IP, and new funding.RANI
UBS Global Healthcare Conference 202413 Jan 2026 - Oral biologics platform advances with strong clinical data, key partnerships, and extended cash runway.RANI
Stifel 2024 Healthcare Conference13 Jan 2026